Fractures — Pathological / Osteoporosis Fractures — Clinical Documentation Guide (2026)

🔍 1. Definition

A pathological fracture is a fracture that occurs through bone that has been weakened by an underlying disease process — not from the level of trauma that would normally be required to break a healthy bone. Unlike traumatic fractures (coded from the S-chapter), pathological fractures result from conditions such as osteoporosis, neoplastic disease, metabolic bone disorders, or bone infection that compromise structural integrity to the point where minimal or no trauma is sufficient to cause a break.

Osteoporosis is the most common systemic skeletal disease leading to pathological fracture. Defined by the National Osteoporosis Foundation and the International Osteoporosis Foundation as reduced bone mineral density (BMD) and deterioration of bone microarchitecture, osteoporosis results in increased skeletal fragility. A BMD T-score of ≤−2.5 SD below the young adult mean at the femoral neck or lumbar spine constitutes osteoporosis per WHO criteria. A T-score between −1.0 and −2.5 defines osteopenia (low bone mass).

The concept of a fragility fracture (also called a low-energy or low-impact fracture) is central to osteoporosis coding: a fracture resulting from forces equivalent to a fall from standing height or less is presumed to be a fragility fracture, and when osteoporosis is documented, linkage to that underlying condition is appropriate for coding purposes per ICD-10-CM FY2026 Official Guidelines.

Pathological fractures are further classified by etiology: fractures due to osteoporosis (M80.x), fractures due to neoplastic disease (M84.5xx), fractures due to other specified diseases (M84.6xx), stress fractures (M84.3xx), pathological fractures NOS (M84.4xx), and the newer category of atypical femoral fractures associated with bisphosphonate therapy (M84.7xx).

🗂️ 2. Alternative Terminology

Correct code assignment often hinges on recognizing the varied clinical language providers use to describe pathological and osteoporosis-related fractures. The following table maps formal ICD-10-CM terminology to equivalent clinical and lay expressions.

🩺 3. Signs & Symptoms

Pathological and osteoporotic fractures present differently from traumatic fractures, often with subtle or insidious onset. Clinical recognition guides appropriate documentation and code assignment.

Vertebral Compression Fractures

• Acute or chronic back pain, often thoracic or lumbar, worsened with movement or weight-bearing
• Height loss (>1.5 cm cumulative or >2 cm over time is clinically significant)
• Kyphosis (dowager's hump / hyperkyphosis) — progressive spinal deformity
• Pain may be absent in up to one-third of cases (silent fractures, incidentally found on imaging)
• Radiculopathy or myelopathy if spinal canal compromise

Hip / Femoral Fractures

• Acute groin, hip, or thigh pain following minimal trauma (ground-level fall)
• Inability to bear weight on affected limb
• Shortened and externally rotated leg (complete displacement)
• Prodromal thigh or groin pain for weeks prior (especially atypical femoral fractures)

Distal Radius / Wrist Fractures

• Wrist pain and deformity after fall on outstretched hand (FOOSH mechanism)
• Dinner-fork deformity (dorsal displacement — Colles type)
• Tenderness at distal radius; limited range of motion

Systemic / General Signs of Underlying Bone Disease

• Low DXA T-score (≤−2.5 at spine or femur = osteoporosis; −1.0 to −2.5 = osteopenia)
• Elevated bone turnover markers (CTX, P1NP) in active remodeling states
• Vertebral fracture assessment (VFA) showing ≥25% vertebral height loss
• Prior fragility fracture (strongest predictor of future fracture)

🧭 4. Differential Diagnosis

Distinguishing pathological fractures from traumatic fractures — and determining the underlying etiology — is critical for accurate code assignment and appropriate clinical management.

📋 5. Clinical Indicators for Coders/CDI

The following indicators should prompt coders and CDI specialists to review documentation for pathological fracture coding opportunities, query needs, or sequencing decisions.

🦴 6. Anatomy & Pathophysiology

Understanding the anatomical sites and pathophysiological mechanisms of pathological fractures is essential for site-specific code selection and accurate laterality assignment.

Skeletal Sites Most Vulnerable to Osteoporotic Fracture

Osteoporosis preferentially affects sites with high trabecular bone content, which turns over faster and is more sensitive to bone loss:

• Vertebral column (M80.08x) — Thoracic (T4–T12) and lumbar (L1–L4) most common; anterior wedge compression is classic
• Proximal femur (M80.05x) — Femoral neck (intracapsular) and intertrochanteric region; hip fracture carries highest mortality (15–20% 1-year mortality in elderly)
• Distal radius (M80.03x) — Colles fracture pattern; often the first fracture in the fragility fracture sequence
• Pelvis (M80.0Ax) — Sacral and pubic rami insufficiency fractures; often underdiagnosed
• Proximal humerus (M80.02x) — Surgical neck fractures from low-energy shoulder falls
• Ribs and sternum (M80.08x) — Can occur from coughing or minor thoracic compression

Pathophysiology of Osteoporosis

Bone is a dynamic tissue undergoing continuous remodeling via the RANK/RANKL/OPG signaling axis. In osteoporosis, there is an imbalance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation (NIH Osteoporosis Overview):

• Postmenopausal osteoporosis (Type I) — Estrogen withdrawal accelerates osteoclast activity; predominantly affects trabecular bone; accounts for most early postmenopausal fractures at wrist and vertebrae
• Age-related osteoporosis (Type II) — Affects both cortical and trabecular bone; occurs in men and women after age 70; associated with hip and vertebral fractures
• Secondary osteoporosis — Caused by glucocorticoid excess (endogenous or exogenous), hypogonadism, malabsorption, renal disease, hyperthyroidism, immobilization

Atypical Femoral Fractures (M84.7xx)

A distinct subtype associated with long-term bisphosphonate therapy (≥3–5 years) or denosumab. Characterized by:

• Location at subtrochanteric region or femoral shaft (NOT neck or intertrochanteric)
• Transverse or short oblique fracture pattern on imaging
• Cortical thickening at the lateral cortex ("beaking" or "dreaded black line")
• Minimal or no trauma history
• Bilateral occurrence in up to 30% of cases — assess contralateral femur

Pathological Fractures in Neoplastic Disease

Metastatic bone disease disrupts normal bone remodeling. Lytic metastases (breast, kidney, thyroid, multiple myeloma) destroy cortical and trabecular bone integrity, leading to pathological fracture through the weakened bone. Blastic lesions (prostate) can also fracture due to disorganized, brittle bone structure. The Mirels scoring system is used clinically to assess fracture risk in metastatic bone disease.

💊 7. Medication Impact / Treatment

Medications play a dual role in pathological fracture coding: as treatments that must be documented to support clinical necessity, and as causative agents that can themselves cause fractures (adverse effects). CDI specialists must recognize both contexts.

Osteoporosis Pharmacotherapy (Fracture Prevention)

• Bisphosphonates — Alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva), zoledronic acid (Reclast IV, J3489). Antiresorptive; reduce vertebral fracture risk 40–70%, hip fracture risk 40–50%. Long-term use (>5 years) associated with atypical femoral fracture risk (M84.7xx) and osteonecrosis of the jaw
• Denosumab (Prolia, J0897) — RANKL inhibitor; subcutaneous injection every 6 months. Reduces vertebral and hip fracture risk similarly to bisphosphonates. Rebound fracture risk upon discontinuation must be documented and transitioned appropriately
• Teriparatide (Forteo, J3110) / Abaloparatide (Tymlos) — Anabolic agents; parathyroid hormone analogues that stimulate new bone formation; used for severe osteoporosis or treatment failures. Significantly reduces vertebral and nonvertebral fracture risk
• Romosozumab (Evenity) — Dual anabolic/antiresorptive; sclerostin inhibitor; used in high-risk patients; 12-month course followed by antiresorptive therapy
• Raloxifene (Evista) — SERM; reduces vertebral but not hip fracture risk; used in postmenopausal women; also reduces breast cancer risk
• Calcium + Vitamin D supplementation — Adjunctive to all pharmacotherapy; inadequate vitamin D documented should be coded separately (E55.x)

Medications That Cause or Worsen Bone Loss (Document for Adverse Effect/Underdosing Coding)

• Glucocorticoids (prednisone, dexamethasone, methylprednisolone) — Most common cause of drug-induced osteoporosis; >5 mg/day prednisone equivalent for >3 months significantly increases fracture risk; requires adverse effect code from T38.0x series if osteoporosis/fracture is documented as related
• Aromatase inhibitors (anastrozole, letrozole) — Used in breast cancer; accelerate bone loss; fracture risk documented with M80.80xx or M84.6xx
• Androgen deprivation therapy (ADT) — Prostate cancer treatment; accelerates bone loss
• Proton pump inhibitors (PPIs) — Long-term use associated with modest increased fracture risk (reduced calcium absorption)
• Loop diuretics, anticonvulsants, heparin, SSRIs — Secondary contributors to bone loss

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides